Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Core Insights - Tevogen Bio Holdings Inc. is focused on immunotherapy and artificial intelligence, with recent presentations highlighting its AI-driven technology for T cell therapies [1][3] - The company aims to develop off-the-shelf, genetically unmodified precision T cell therapies to address significant unmet medical needs in infectious diseases and cancers [4][5] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes for therapeutic development [4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to artificial intelligence [4] Recent Events - Mittul Mehta, the Chief Information Officer, presented at the AI x Bio Philly event, discussing Tevogen.AI's proprietary technology that accelerates the discovery and development of precision T cell therapies [1][3][2] - The event gathered innovators and investors to explore the impact of AI on biotechnology, showcasing the convergence of these fields [2]